vs
Clearfield, Inc.（CLFD）与Xtant Medical Holdings, Inc.（XTNT）财务数据对比。点击上方公司名可切换其他公司
Clearfield, Inc.的季度营收约是Xtant Medical Holdings, Inc.的1.1倍（$34.3M vs $32.4M），Xtant Medical Holdings, Inc.净利率更高（0.2% vs -1.8%，领先2.0%），Xtant Medical Holdings, Inc.同比增速更快（2.7% vs -3.2%），Xtant Medical Holdings, Inc.自由现金流更多（$5.0M vs $-2.4M），过去两年Xtant Medical Holdings, Inc.的营收复合增速更高（7.7% vs -3.5%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
Xtant Medical Holdings是一家全球医疗技术企业，主营骨科生物制剂、神经外科器械及再生医学解决方案，为骨科与神经科诊疗机构提供脊柱手术耗材、骨再生产品等，服务覆盖北美、欧洲及亚太多个地区市场。
CLFD vs XTNT — 直观对比
营收规模更大
CLFD
是对方的1.1倍
$32.4M
营收增速更快
XTNT
高出5.9%
-3.2%
净利率更高
XTNT
高出2.0%
-1.8%
自由现金流更多
XTNT
多$7.4M
$-2.4M
两年增速更快
XTNT
近两年复合增速
-3.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $32.4M |
| 净利润 | $-614.0K | $57.0K |
| 毛利率 | 33.2% | 54.9% |
| 营业利润率 | -5.3% | -2.9% |
| 净利率 | -1.8% | 0.2% |
| 营收同比 | -3.2% | 2.7% |
| 净利润同比 | 67.8% | 101.8% |
| 每股收益（稀释后） | $-0.04 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDXTNT
| Q4 25 | $34.3M | $32.4M | ||
| Q3 25 | $23.4M | $33.3M | ||
| Q2 25 | $49.9M | $35.4M | ||
| Q1 25 | $47.2M | $32.9M | ||
| Q4 24 | $29.7M | $31.5M | ||
| Q3 24 | $5.6M | $27.9M | ||
| Q2 24 | $48.8M | $29.9M | ||
| Q1 24 | $36.9M | $27.9M |
净利润CLFDXTNT
| Q4 25 | $-614.0K | $57.0K | ||
| Q3 25 | $-9.1M | $1.3M | ||
| Q2 25 | $1.6M | $3.5M | ||
| Q1 25 | $1.3M | $58.0K | ||
| Q4 24 | $-1.9M | $-3.2M | ||
| Q3 24 | — | $-5.0M | ||
| Q2 24 | $-447.0K | $-3.9M | ||
| Q1 24 | $-5.9M | $-4.4M |
毛利率CLFDXTNT
| Q4 25 | 33.2% | 54.9% | ||
| Q3 25 | 53.2% | 66.1% | ||
| Q2 25 | 30.5% | 68.6% | ||
| Q1 25 | 30.1% | 61.5% | ||
| Q4 24 | 29.2% | 50.9% | ||
| Q3 24 | — | 58.4% | ||
| Q2 24 | 21.9% | 62.1% | ||
| Q1 24 | 7.7% | 62.1% |
营业利润率CLFDXTNT
| Q4 25 | -5.3% | -2.9% | ||
| Q3 25 | 10.3% | 7.6% | ||
| Q2 25 | 3.0% | 13.1% | ||
| Q1 25 | 0.6% | 3.2% | ||
| Q4 24 | -6.9% | -6.0% | ||
| Q3 24 | — | -13.5% | ||
| Q2 24 | -4.7% | -9.8% | ||
| Q1 24 | -26.4% | -12.4% |
净利率CLFDXTNT
| Q4 25 | -1.8% | 0.2% | ||
| Q3 25 | -38.8% | 3.9% | ||
| Q2 25 | 3.2% | 10.0% | ||
| Q1 25 | 2.8% | 0.2% | ||
| Q4 24 | -6.4% | -10.0% | ||
| Q3 24 | — | -18.0% | ||
| Q2 24 | -0.9% | -12.9% | ||
| Q1 24 | -16.0% | -15.8% |
每股收益（稀释后）CLFDXTNT
| Q4 25 | $-0.04 | $0.00 | ||
| Q3 25 | $-0.65 | $0.01 | ||
| Q2 25 | $0.11 | $0.02 | ||
| Q1 25 | $0.09 | $0.00 | ||
| Q4 24 | $-0.13 | $-0.02 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | $-0.04 | $-0.03 | ||
| Q1 24 | $-0.40 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $17.1M |
| 总债务越低越好 | — | $11.0M |
| 股东权益账面价值 | $249.7M | $51.0M |
| 总资产 | $268.1M | $94.1M |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资CLFDXTNT
| Q4 25 | $96.4M | $17.1M | ||
| Q3 25 | $106.0M | $10.4M | ||
| Q2 25 | $117.2M | $6.9M | ||
| Q1 25 | $112.0M | $5.0M | ||
| Q4 24 | $113.0M | $6.2M | ||
| Q3 24 | $129.0M | $6.6M | ||
| Q2 24 | $123.8M | $5.4M | ||
| Q1 24 | $142.9M | $4.5M |
总债务CLFDXTNT
| Q4 25 | — | $11.0M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | — | $22.3M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | $2.2M | $19.1M | ||
| Q2 24 | $2.1M | $21.8M | ||
| Q1 24 | — | $16.8M |
股东权益CLFDXTNT
| Q4 25 | $249.7M | $51.0M | ||
| Q3 25 | $256.2M | $50.4M | ||
| Q2 25 | $264.5M | $48.5M | ||
| Q1 25 | $265.9M | $43.9M | ||
| Q4 24 | $267.4M | $43.0M | ||
| Q3 24 | $275.8M | $45.7M | ||
| Q2 24 | $274.6M | $45.0M | ||
| Q1 24 | $279.2M | $47.7M |
总资产CLFDXTNT
| Q4 25 | $268.1M | $94.1M | ||
| Q3 25 | $306.2M | $106.3M | ||
| Q2 25 | $314.7M | $103.5M | ||
| Q1 25 | $310.9M | $95.8M | ||
| Q4 24 | $303.2M | $93.8M | ||
| Q3 24 | $315.3M | $98.9M | ||
| Q2 24 | $318.1M | $95.6M | ||
| Q1 24 | $315.4M | $93.9M |
负债/权益比CLFDXTNT
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | 0.01× | 0.42× | ||
| Q2 24 | 0.01× | 0.48× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $5.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 15.4% |
| 资本支出强度资本支出/营收 | 2.9% | 1.2% |
| 现金转化率经营现金流/净利润 | — | 94.39× |
| 过去12个月自由现金流最近4个季度 | — | $10.2M |
8季度趋势，按日历期对齐
经营现金流CLFDXTNT
| Q4 25 | $-1.4M | $5.4M | ||
| Q3 25 | — | $4.6M | ||
| Q2 25 | $7.9M | $1.3M | ||
| Q1 25 | $3.0M | $1.3M | ||
| Q4 24 | $7.2M | $665.0K | ||
| Q3 24 | $22.2M | $-1.7M | ||
| Q2 24 | $4.0M | $-5.1M | ||
| Q1 24 | $-5.7M | $-5.8M |
自由现金流CLFDXTNT
| Q4 25 | $-2.4M | $5.0M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | $7.5M | $910.0K | ||
| Q1 25 | $654.0K | $87.0K | ||
| Q4 24 | $5.1M | $-7.0K | ||
| Q3 24 | $18.2M | $-3.8M | ||
| Q2 24 | $2.8M | $-5.7M | ||
| Q1 24 | $-7.7M | $-6.5M |
自由现金流率CLFDXTNT
| Q4 25 | -7.1% | 15.4% | ||
| Q3 25 | — | 12.6% | ||
| Q2 25 | 15.1% | 2.6% | ||
| Q1 25 | 1.4% | 0.3% | ||
| Q4 24 | 17.1% | -0.0% | ||
| Q3 24 | 323.0% | -13.7% | ||
| Q2 24 | 5.8% | -18.9% | ||
| Q1 24 | -20.8% | -23.4% |
资本支出强度CLFDXTNT
| Q4 25 | 2.9% | 1.2% | ||
| Q3 25 | 2.0% | 1.3% | ||
| Q2 25 | 0.8% | 1.0% | ||
| Q1 25 | 5.1% | 3.6% | ||
| Q4 24 | 7.0% | 2.1% | ||
| Q3 24 | 71.4% | 7.5% | ||
| Q2 24 | 2.5% | 1.9% | ||
| Q1 24 | 5.3% | 2.8% |
现金转化率CLFDXTNT
| Q4 25 | — | 94.39× | ||
| Q3 25 | — | 3.53× | ||
| Q2 25 | 4.93× | 0.36× | ||
| Q1 25 | 2.30× | 22.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLFD
暂无分部数据
XTNT
| Orthobiologics | $18.3M | 57% |
| Spinal Implant | $9.4M | 29% |
| License Revenue | $4.6M | 14% |
